Back to Newsroom

Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

SAN DIEGO, Oct. 20, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that a late-breaking abstract detailing results from the company’s multicenter Phase 2 Portal Hypertension clinical trial in patients with liver cirrhosis has been accepted for oral presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015.

Click here to read more